Finbar (ASX:FRI) Raises Dividend, Starts Closing The Valuation Gap
Finbar (ASX:FRI) raised its dividend but not by as much as I had hoped for.
Company Coverage
Rightcrowd’s (ASX:RCW) Contracted ARR Meets My Expectations
Including an important clarification regarding the way Rightcrowd reports ARR.
Eroad (ASX:ERD) Improves Growth And Acquires Coretex
Eroad has more success in New Zealand than the USA, but acquiring Coretex may well be the best move to drive international growth faster.
8Common (ASX:8CO) Share Price Is Lower On Quarterly Report
8Common (ASX:8CO) keeps promising growth but the receipts from customers are down.
The Truth About Austco Healthcare (ASX: AHC) Shares
Austco Healthcare (ASX:AHC) has profits, a global client base, and potential for post-pandemic growth. But its chequered past haunts the stock.
Objective Corporation (ASX: OCL) Reports Record Results In FY2021
Objective Corporation (ASX:OCL) has reported record revenue, record profit, and record annualised recurring revenue, in FY 2021. But is its valuation too punchy?
Xref Share Price Flies As It Reaches An Inflection Point (ASX:XF1)
The Xref (ASX:XF1) share price has gained over 16% on a record result which sees the company achieve free cash flow breakeven in FY2021.
Dicker Data (ASX:DDR) Forecasts Record Profit
Dicker Data is forecasting a record profit which allays my concerns about its transition to a bigger warehouse.
Directors Keep Buying Shares Of This Cyclical Small-Cap
One director of this boring dividend payer just bought a fair chunk of shares at slightly above the current price.
The Truth About The Redbubble (ASX: RBL) Business Model
The Redbubble (ASX: RBL) share price gained over 500% during the pandemic, but the business model is badly misunderstood.
Checking In On Damstra (ASX: DTC)
Damstra’s share price is back where it was a year ago. What went wrong, and is this an opportunity or the time to give up?
Why IntelliHR (ASX:IHR) Catches My Eye
IntelliHR (ASX: IHR) looks to have reached an inflection point with its revenue growth, but it’s a long way from profitability. Here’s why it’s worth watching.
Medical Developments International (ASX: MVP) Providing An Alternative To Opioid Addiction
Medical Developments International (ASX:MVP) shares look attractive at current prices given the potential for significant Penthrox sales growth.
2 New “Risk On” Small Caps I Bought This Week
I’m finding these 5 (3 old, 2 new) micro-caps tempting at current prices…
The Flaw In Macquarie Bank’s Sezzle (ASX:SZL) Coverage
Macquarie notes that Sezzle’s Appstore ranking has improved, but their analysis barely scratches the surface. Are Sezzle (ASX:SZL) shareholders in the dark?
3 Prospective Small Cap Stocks Directors Are Buying
These three stocks have seen insider buying and have decent prospects in the next few years.
Eroad On The Right Track FY2021 Results (ASX:ERD)
Eroad’s FY2021 results showed weak half-on-half revenue growth, but there are signs of an exciting future.
Claude Chats Nanosonics and Xero On The Call
In this video, I explain why I’m currently accumulating Nanosonics shares…
The Truth About The Appen (ASX: APX) Business Model
Appen (ASX: APX) shares are a potentially interesting investment, but investors should focus on the key drivers of the business, not EBITDA multiples.